Pipeline

BioArctic’s portfolio has projects in several focus areas and in various phases from discovery through clinical development.

Antibody Project [ Alzheimer’s disease ]
Project
Lecanemab (IV)1
Partner
Eisai
Research Preclinical Phase 1 Phase 2 Phase 3 Reg. application Market
Antibody Project [ Alzheimer’s disease ]
Project
Lecanemab (s.c)2
Partner
Eisai
Research Preclinical Phase 1 Phase 2 Phase 3 Reg. application Market
Antibody Project [ Alzheimer’s disease ]
Project
Lecanemab
(presymptomatic treatment)
Partner
Eisai
Research Preclinical Phase 1 Phase 2 Phase 3 Reg. application Market
Antibody Project [ Alzheimer’s disease ]
Project
Lecanemab back-up
Partner
Eisai
Research Preclinical Phase 1 Phase 2 Phase 3 Reg. application Market
Antibody Project [ Alzheimer’s disease ]
Project
BAN1503
(PyroGlu Aß)
Partner
BMS3
Research Preclinical Phase 1 Phase 2 Phase 3 Reg. application Market
Antibody Project [ Parkinson's disease ]
Project
Exidavnemab
(a-synuclein)
Research Preclinical Phase 1 Phase 2 Phase 3 Reg. application Market
Antibody Project [ Other CNS diseases ]
Project
Lecanemab
(other indications)
Research Preclinical Phase 1 Phase 2 Phase 3 Reg. application Market
Antibody Project [ Other CNS diseases ]
Project
ND3014 (TDP-43, ALS)
Research Preclinical Phase 1 Phase 2 Phase 3 Reg. application Market
Antibody Project
Project
Partner
Research
Preclinical
Phase 1
Phase 2
Phase 3
Reg. application
Market
Alzheimer’s disease
Lecanemab (IV)1
Eisai
Lecanemab (s.c)2
Eisai
Lecanemab
(presymptomatic treatment)
Eisai
Lecanemab back-up
Eisai
BAN1503
(PyroGlu Aß)
BMS3
Parkinson's disease
Exidavnemab
(a-synuclein)
Other CNS diseases
Lecanemab
(other indications)
ND3014 (TDP-43, ALS)
BrainTransporter™ [ Alzheimer's disease ]
Project
BAN2803
(PyroGlu Aß with BrainTransporter)5
Partner
BMS3
Research Preclinical Phase 1 Phase 2 Phase 3 Reg. application Market
BrainTransporter™ [ Alzheimer's disease ]
Project
BAN2802
Partner
Eisai4
Research Preclinical Phase 1 Phase 2 Phase 3 Reg. application Market
BrainTransporter™ [ Parkinson's disease ]
Project
PD-BT2238
(a-synuclein with BrainTransporter)
Research Preclinical Phase 1 Phase 2 Phase 3 Reg. application Market
BrainTransporter™ [ ALS ]
Project
ND-BT3814
(TDP-43 with BrainTransporter)
Research Preclinical Phase 1 Phase 2 Phase 3 Reg. application Market
BrainTransporter™ [ Gaucher disease ]
Project
GD-BT6822
(Gcase with BrainTransporter)
Research Preclinical Phase 1 Phase 2 Phase 3 Reg. application Market
BrainTransporter™ [ Neurodegeneration ]
Project
ND-BT8825
Partner
Novartis
Research Preclinical Phase 1 Phase 2 Phase 3 Reg. application Market
BrainTransporter™ [ Platform ]
Project
Technology- and modality development
Research Preclinical Phase 1 Phase 2 Phase 3 Reg. application Market
BrainTransporter™
Project
Partner
Research
Preclinical
Phase 1
Phase 2
Phase 3
Reg. application
Market
Alzheimer's disease
BAN2803
(PyroGlu Aß with BrainTransporter)5
BMS3
BAN2802
Eisai4
Parkinson's disease
PD-BT2238
(a-synuclein with BrainTransporter)
ALS
ND-BT3814
(TDP-43 with BrainTransporter)
Gaucher disease
GD-BT6822
(Gcase with BrainTransporter)
Neurodegeneration
ND-BT8825
Novartis
Platform
Technology- and modality development

    1. Intravenous treatment
    2. Subcutaneous treatment
    3. A license agreement was signed with Bristol Myers Squibb on December 19, 2024, and entered into force on February 20th, 2025.
    4. Research evaluation agreement with Eisai
    5. BrainTransporter